Cargando…

Atherosclerotic Plaque Fissuration and Clinical Outcomes in Pre-Diabetics vs. Normoglycemics Patients Affected by Asymptomatic Significant Carotid Artery Stenosis at 2 Years of Follow-Up: Role of microRNAs Modulation: The ATIMIR Study

Atherosclerotic plaque instability and rupture in patients with asymptomatic carotid artery stenosis (ACAS) is a leading cause of major adverse cardiac events (MACE). This could be mainly evidenced in patients with pre-diabetes. Indeed, the altered glucose homeostasis and insulin resistance could ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Sardu, Celestino, Modugno, Pietro, Castellano, Gaetano, Scisciola, Lucia, Barbieri, Michelangela, Petrella, Lella, Fanelli, Mara, Macchia, Gabriella, Caradonna, Eugenio, Massetti, Massimo, Paolisso, Giuseppe, Marfella, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068301/
https://www.ncbi.nlm.nih.gov/pubmed/33917851
http://dx.doi.org/10.3390/biomedicines9040401
_version_ 1783683004018720768
author Sardu, Celestino
Modugno, Pietro
Castellano, Gaetano
Scisciola, Lucia
Barbieri, Michelangela
Petrella, Lella
Fanelli, Mara
Macchia, Gabriella
Caradonna, Eugenio
Massetti, Massimo
Paolisso, Giuseppe
Marfella, Raffaele
author_facet Sardu, Celestino
Modugno, Pietro
Castellano, Gaetano
Scisciola, Lucia
Barbieri, Michelangela
Petrella, Lella
Fanelli, Mara
Macchia, Gabriella
Caradonna, Eugenio
Massetti, Massimo
Paolisso, Giuseppe
Marfella, Raffaele
author_sort Sardu, Celestino
collection PubMed
description Atherosclerotic plaque instability and rupture in patients with asymptomatic carotid artery stenosis (ACAS) is a leading cause of major adverse cardiac events (MACE). This could be mainly evidenced in patients with pre-diabetes. Indeed, the altered glucose homeostasis and insulin resistance could cause over-inflammation of atherosclerotic plaque, favoring its conversion to unstable phenotype with rupture and MACE. Notably, metformin therapy reducing the metabolic distress and the inflammatory burden could reduce MACE in ACAS patients with pre-diabetes. In this setting, the microRNAs (miRs) could be used as molecular biomarkers of atherosclerosis progression, plaque rupture, and worse prognosis in normoglycemics (NG) versus pre-diabetics metformin users (PDMU) versus pre-diabetics non-metformin users (PDNMU). However, our study aimed to investigate a wide miRNA panel in peripheral blood exosomes from patients with ACAS divided in NG versus PDMU versus PDNMU, and to associate the circulating miRNA expression profiles with MACE at 2 years of follow-up after endarterectomy. The study included 234 patients with ACAS divided into NG (n = 125), PDNMU (n = 73), and PDMU (n = 36). The miRs’ expression profiles of circulating exosomes were determined at baseline and at 2 years of follow-up by Affymetrix microarrays from the patients’ plasma samples from any study cohort. Then we collected and analyzed MACE at 2 years of follow-up in NG versus PDMU versus PDNMU. Prediabetics versus NG had over-inflammation (p < 0.05) and over expressed miR-24 and miR-27 at baseline. At 2 years of follow-up, PDNMU versus NG, PDMU versus NG, and PDNMU versus PDMU over-expressed inflammatory markers and miR-24, miR-27, miR-100, miR-126, and miR-133 (p < 0.05). Finally, at the end of follow-up, we observed a significant difference about MACE comparing PDNMU versus NG (n = 27 (36.9%) versus n = 8 (6.4%); p < 0.05), PDNMU versus PDMU (n = 27 (36.9%) versus n = 6 (16.6%); p < 0.05); and PDMU versus NG (n = 6 (16.6%) versus n = 8 (6.4%); p < 0.05). Admission glucose values (HR (hazard ratio) 1.020, CI (confidence of interval) 95% (1.001–1.038), p = 0.029), atheromatous carotid plaque (HR 5.373, CI 95% (1.251–11.079), p = 0.024), and miR-24 (HR 3.842, CI 95% (1.768–19.222), p = 0.011) predicted MACE at 2 years of follow-up. Specific circulating miRs could be over-expressed in pre-diabetics and specifically in PDNMU versus PDMU after endarterectomy. MiR24, hyperglycemia, and atheromatous plaque could predict MACE at 2 years of follow-up.
format Online
Article
Text
id pubmed-8068301
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80683012021-04-25 Atherosclerotic Plaque Fissuration and Clinical Outcomes in Pre-Diabetics vs. Normoglycemics Patients Affected by Asymptomatic Significant Carotid Artery Stenosis at 2 Years of Follow-Up: Role of microRNAs Modulation: The ATIMIR Study Sardu, Celestino Modugno, Pietro Castellano, Gaetano Scisciola, Lucia Barbieri, Michelangela Petrella, Lella Fanelli, Mara Macchia, Gabriella Caradonna, Eugenio Massetti, Massimo Paolisso, Giuseppe Marfella, Raffaele Biomedicines Article Atherosclerotic plaque instability and rupture in patients with asymptomatic carotid artery stenosis (ACAS) is a leading cause of major adverse cardiac events (MACE). This could be mainly evidenced in patients with pre-diabetes. Indeed, the altered glucose homeostasis and insulin resistance could cause over-inflammation of atherosclerotic plaque, favoring its conversion to unstable phenotype with rupture and MACE. Notably, metformin therapy reducing the metabolic distress and the inflammatory burden could reduce MACE in ACAS patients with pre-diabetes. In this setting, the microRNAs (miRs) could be used as molecular biomarkers of atherosclerosis progression, plaque rupture, and worse prognosis in normoglycemics (NG) versus pre-diabetics metformin users (PDMU) versus pre-diabetics non-metformin users (PDNMU). However, our study aimed to investigate a wide miRNA panel in peripheral blood exosomes from patients with ACAS divided in NG versus PDMU versus PDNMU, and to associate the circulating miRNA expression profiles with MACE at 2 years of follow-up after endarterectomy. The study included 234 patients with ACAS divided into NG (n = 125), PDNMU (n = 73), and PDMU (n = 36). The miRs’ expression profiles of circulating exosomes were determined at baseline and at 2 years of follow-up by Affymetrix microarrays from the patients’ plasma samples from any study cohort. Then we collected and analyzed MACE at 2 years of follow-up in NG versus PDMU versus PDNMU. Prediabetics versus NG had over-inflammation (p < 0.05) and over expressed miR-24 and miR-27 at baseline. At 2 years of follow-up, PDNMU versus NG, PDMU versus NG, and PDNMU versus PDMU over-expressed inflammatory markers and miR-24, miR-27, miR-100, miR-126, and miR-133 (p < 0.05). Finally, at the end of follow-up, we observed a significant difference about MACE comparing PDNMU versus NG (n = 27 (36.9%) versus n = 8 (6.4%); p < 0.05), PDNMU versus PDMU (n = 27 (36.9%) versus n = 6 (16.6%); p < 0.05); and PDMU versus NG (n = 6 (16.6%) versus n = 8 (6.4%); p < 0.05). Admission glucose values (HR (hazard ratio) 1.020, CI (confidence of interval) 95% (1.001–1.038), p = 0.029), atheromatous carotid plaque (HR 5.373, CI 95% (1.251–11.079), p = 0.024), and miR-24 (HR 3.842, CI 95% (1.768–19.222), p = 0.011) predicted MACE at 2 years of follow-up. Specific circulating miRs could be over-expressed in pre-diabetics and specifically in PDNMU versus PDMU after endarterectomy. MiR24, hyperglycemia, and atheromatous plaque could predict MACE at 2 years of follow-up. MDPI 2021-04-08 /pmc/articles/PMC8068301/ /pubmed/33917851 http://dx.doi.org/10.3390/biomedicines9040401 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sardu, Celestino
Modugno, Pietro
Castellano, Gaetano
Scisciola, Lucia
Barbieri, Michelangela
Petrella, Lella
Fanelli, Mara
Macchia, Gabriella
Caradonna, Eugenio
Massetti, Massimo
Paolisso, Giuseppe
Marfella, Raffaele
Atherosclerotic Plaque Fissuration and Clinical Outcomes in Pre-Diabetics vs. Normoglycemics Patients Affected by Asymptomatic Significant Carotid Artery Stenosis at 2 Years of Follow-Up: Role of microRNAs Modulation: The ATIMIR Study
title Atherosclerotic Plaque Fissuration and Clinical Outcomes in Pre-Diabetics vs. Normoglycemics Patients Affected by Asymptomatic Significant Carotid Artery Stenosis at 2 Years of Follow-Up: Role of microRNAs Modulation: The ATIMIR Study
title_full Atherosclerotic Plaque Fissuration and Clinical Outcomes in Pre-Diabetics vs. Normoglycemics Patients Affected by Asymptomatic Significant Carotid Artery Stenosis at 2 Years of Follow-Up: Role of microRNAs Modulation: The ATIMIR Study
title_fullStr Atherosclerotic Plaque Fissuration and Clinical Outcomes in Pre-Diabetics vs. Normoglycemics Patients Affected by Asymptomatic Significant Carotid Artery Stenosis at 2 Years of Follow-Up: Role of microRNAs Modulation: The ATIMIR Study
title_full_unstemmed Atherosclerotic Plaque Fissuration and Clinical Outcomes in Pre-Diabetics vs. Normoglycemics Patients Affected by Asymptomatic Significant Carotid Artery Stenosis at 2 Years of Follow-Up: Role of microRNAs Modulation: The ATIMIR Study
title_short Atherosclerotic Plaque Fissuration and Clinical Outcomes in Pre-Diabetics vs. Normoglycemics Patients Affected by Asymptomatic Significant Carotid Artery Stenosis at 2 Years of Follow-Up: Role of microRNAs Modulation: The ATIMIR Study
title_sort atherosclerotic plaque fissuration and clinical outcomes in pre-diabetics vs. normoglycemics patients affected by asymptomatic significant carotid artery stenosis at 2 years of follow-up: role of micrornas modulation: the atimir study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068301/
https://www.ncbi.nlm.nih.gov/pubmed/33917851
http://dx.doi.org/10.3390/biomedicines9040401
work_keys_str_mv AT sarducelestino atheroscleroticplaquefissurationandclinicaloutcomesinprediabeticsvsnormoglycemicspatientsaffectedbyasymptomaticsignificantcarotidarterystenosisat2yearsoffollowuproleofmicrornasmodulationtheatimirstudy
AT modugnopietro atheroscleroticplaquefissurationandclinicaloutcomesinprediabeticsvsnormoglycemicspatientsaffectedbyasymptomaticsignificantcarotidarterystenosisat2yearsoffollowuproleofmicrornasmodulationtheatimirstudy
AT castellanogaetano atheroscleroticplaquefissurationandclinicaloutcomesinprediabeticsvsnormoglycemicspatientsaffectedbyasymptomaticsignificantcarotidarterystenosisat2yearsoffollowuproleofmicrornasmodulationtheatimirstudy
AT scisciolalucia atheroscleroticplaquefissurationandclinicaloutcomesinprediabeticsvsnormoglycemicspatientsaffectedbyasymptomaticsignificantcarotidarterystenosisat2yearsoffollowuproleofmicrornasmodulationtheatimirstudy
AT barbierimichelangela atheroscleroticplaquefissurationandclinicaloutcomesinprediabeticsvsnormoglycemicspatientsaffectedbyasymptomaticsignificantcarotidarterystenosisat2yearsoffollowuproleofmicrornasmodulationtheatimirstudy
AT petrellalella atheroscleroticplaquefissurationandclinicaloutcomesinprediabeticsvsnormoglycemicspatientsaffectedbyasymptomaticsignificantcarotidarterystenosisat2yearsoffollowuproleofmicrornasmodulationtheatimirstudy
AT fanellimara atheroscleroticplaquefissurationandclinicaloutcomesinprediabeticsvsnormoglycemicspatientsaffectedbyasymptomaticsignificantcarotidarterystenosisat2yearsoffollowuproleofmicrornasmodulationtheatimirstudy
AT macchiagabriella atheroscleroticplaquefissurationandclinicaloutcomesinprediabeticsvsnormoglycemicspatientsaffectedbyasymptomaticsignificantcarotidarterystenosisat2yearsoffollowuproleofmicrornasmodulationtheatimirstudy
AT caradonnaeugenio atheroscleroticplaquefissurationandclinicaloutcomesinprediabeticsvsnormoglycemicspatientsaffectedbyasymptomaticsignificantcarotidarterystenosisat2yearsoffollowuproleofmicrornasmodulationtheatimirstudy
AT massettimassimo atheroscleroticplaquefissurationandclinicaloutcomesinprediabeticsvsnormoglycemicspatientsaffectedbyasymptomaticsignificantcarotidarterystenosisat2yearsoffollowuproleofmicrornasmodulationtheatimirstudy
AT paolissogiuseppe atheroscleroticplaquefissurationandclinicaloutcomesinprediabeticsvsnormoglycemicspatientsaffectedbyasymptomaticsignificantcarotidarterystenosisat2yearsoffollowuproleofmicrornasmodulationtheatimirstudy
AT marfellaraffaele atheroscleroticplaquefissurationandclinicaloutcomesinprediabeticsvsnormoglycemicspatientsaffectedbyasymptomaticsignificantcarotidarterystenosisat2yearsoffollowuproleofmicrornasmodulationtheatimirstudy